Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
U.S. Stock Insider Trading | BeiGene disclosed four insider trading transactions on March 13
On March 13, 2026, BeiGene, Ltd. (ONC) disclosed four insider trading transactions by company insiders. Executive Lee Chan Henry sold 341 shares on March 11, 2026.
【Recent Insider Transactions】
【Company Information】
BeiGene, Ltd.’s principal business is the research, development, manufacturing, and commercialization of innovative drugs. The company’s main products include BaiYueZe, BaiZeAn, BaiHuiZe, AnJiaWei, BeiLiTuo, KaiLuoSi, SaWenKe, KaiZeBai, PuBeiXi (an AnWeiDing biosimilar drug), BaiTuoWei (gonadotropin-releasing hormone microspheres for injection), TaiFeiLe (dabrafenib), MaiJiNing (trametinib), WeiQuanTe (pazopanib), FeiNiTuo (everolimus), and ZanKeDa (ceritinib). As of the end of this reporting period, the company and its controlling subsidiaries hold, among others, 64 U.S. invention patents, 67 Chinese invention patents, 30 Japanese invention patents, 15 European invention patents, and 135 invention patents in other countries or regions.